U.S. Markets open in 6 hrs 23 mins
  • S&P Futures

    3,784.50
    -18.75 (-0.49%)
     
  • Dow Futures

    30,233.00
    -132.00 (-0.43%)
     
  • Nasdaq Futures

    11,580.00
    -60.75 (-0.52%)
     
  • Russell 2000 Futures

    1,769.40
    -12.10 (-0.68%)
     
  • Crude Oil

    86.59
    +0.07 (+0.08%)
     
  • Gold

    1,734.40
    +3.90 (+0.23%)
     
  • Silver

    20.99
    -0.11 (-0.54%)
     
  • EUR/USD

    0.9971
    -0.0015 (-0.1496%)
     
  • 10-Yr Bond

    3.6170
    0.0000 (0.00%)
     
  • Vix

    29.07
    -1.03 (-3.42%)
     
  • GBP/USD

    1.1459
    -0.0015 (-0.1341%)
     
  • USD/JPY

    144.3050
    +0.1060 (+0.0735%)
     
  • BTC-USD

    20,242.15
    +395.20 (+1.99%)
     
  • CMC Crypto 200

    459.05
    +13.62 (+3.06%)
     
  • FTSE 100

    7,086.46
    0.00 (0.00%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

Franchise Global Reports Second Quarter 2022 Financial Results; Revenues Increased by $13.1 Million YoY to $13.5 Million

·3 min read

For the quarter, the Company's German reportable segment achieved revenues of $13.5 million, gross profit of $1.0 million and net income of $0.1 million

For the year-to-date period, the Company's Germany reportable segment achieved revenues of $30.1 million, gross profit of $2.1 million and net income of $0.4 million.

VANCOUVER, BC, Aug. 26, 2022 /CNW/ - Franchise Global Health Inc. ("Franchise Global" or the "Company") (TSXV: FGH) (FRA: WV4A) is pleased to announce its results for the second quarter of 2022.

Clifford Starke, Executive Chairman and Chief Executive Officer of Franchise Global, stated, "The Company's German reportable segment continued its momentum in the quarter. Our results reflect the stability of our pharmaceutical business during a period of market volatility."

Mr. Starke continued, "We exited the quarter with total liquidity of $4.4 million, including cash of $2.4 million, and net assets of $9.3 million. Sales in the quarter of $13.5 million and $30.1 million year-to-date do not include $2.0 million of shipments made in early July for which arrangements were finalized in the quarter. Sales in the quarter were further affected by the strength of the Canadian dollar relative to the Euro as the Company's sales are in Euros while the Company reports in Canadian dollars".

Mr. Starke concluded, "Our solid distribution platform will prove to be invaluable as Germany continues to expedite the process towards legalization of recreational cannabis."

FINANCIAL AND OPERATING HIGHLIGHTS FOR THE QUARTER

  • Revenues of $13.5 million, an increase of $13.1 million from the second quarter of 2021.

  • Gross profit of $1.0 million, an increase of $0.8 million from the second quarter of 2021.

  • Net loss of $1.1 million compared to $1.0 in the second quarter of 2021.

  • The Company's German reportable segment achieved net income of $0.1 million.

FINANCIAL AND OPERATING HIGHLIGHTS FOR THE YEAR-TO-DATE

  • Revenues of $30.1 million, an increase of $29.4 million from the comparative period of 2021.

  • Gross profit of $2.1 million, an increase of $1.9 million from the comparative period of 2021.

  • Net loss of $18.1 million. Excluding one-time listing expenses of $15.6 million, share-based compensation of $0.8 million and impairment expense of $0.3 million, net loss was $1.4 million.

  • The Company's German reportable segment achieved net income of $0.4 million.

SECOND QUARTER 2022 FINANCIAL RESULTS

Revenues
Revenues increased 3,275% from $0.4 million in the second quarter of 2021 to $13.5 million in the second quarter of 2022. The increase is primarily due to acquisition of Phatebo GmbH ("Phatebo"), which contributed $13.4 million to revenues in the second quarter of 2022. The Company acquired 100% of Phatebo on December 31, 2021.

Gross Profit
Gross profit for the second quarter of 2022 was $1.0 million, up $0.9 million or 900% from $0.1 million for the same period in the prior year.

Net Loss
Net loss for the second quarter of 2022 was $1.1 million. Excluding corporate costs and other reportable segments, the Company's German reportable segment achieved net income of $0.1 million.

Liquidity
As at June 30, 2022, the company has total liquidity of $4.4 million consisting of cash of $2.4 million as well as $2.0 million (€1.5 million) in undrawn capacity on Phatebo's lines of credit, as well as net assets of $9.3 million.

CONFERENCE CALL

A conference call hosted by senior management will be held on Tuesday, August 30, 2022 at 9:00 AM EST. Please join the conference call approximately ten minutes prior to the scheduled start time.

Dial-in details for the conference call are as follows:

Toronto local or International: 1-416-915-3239

Toll-Free (North America): 1-800-319-4610

About Franchise Global

Franchise Global, through its subsidiaries, is a multi-national operator in the medical cannabis and pharmaceutical industries, with principal operations in Germany and with operations, assets, strategic partnerships and investments internationally. Franchise Global's business objective is to develop a fully‑integrated, leading European medical cannabis business, with the goal of providing high-quality pharmaceutical grade medical cannabis to distribution partners and, ultimately, to patients, at competitive prices.  For more information please visit www.franchiseglobalhealth.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.

Cautionary Statement Regarding Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable securities laws, including without limitation statements regarding the business of Franchise Global and its prospects. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on management's current expectations, estimates, beliefs and/or opinions and is based on information currently available to them (including information obtained from third party industry analysts and other third-party sources) and on assumptions they believe not to be unreasonable in light of all of the circumstances.

By its nature, forward-looking information is subject to both known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Readers are cautioned to not place undue reliance on forward-looking information. Please refer to the filing statement of the Company available on the Company's SEDAR profile at www.sedar.com for more details on the risks and uncertainties faced by Franchise Global. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement, and the Company undertakes no obligation, and does not intend, to update any forward-looking information contained in this news release, whether as a result of new information, future developments, or otherwise, except as otherwise required by applicable law.

SOURCE Franchise Global Health Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/August2022/26/c5860.html